1) 榊原隆次, 舘野冬樹, 岸 雅彦, 他 : 脳血管障害による神経因性膀胱(認知症を含めて). 臨泌68 : 221─226, 2014
2) 榊原隆次(編) : 神経因性膀胱ベッドサイドマニュアル. 中外医学社, 東京, 2014
3) Sakakibara R, Panicker J, Fowler CJ, et al : “Vascular incontinence”: incontinence in the elderly due to ischemic white matter changes. Neurology International 4 : e13, 2012
4) Andrew J and Nathan PW : Lesions of the anterior frontal lobes and disturbances of micturition and defaecation. Brain 87 : 233─262, 1964
5) Fowler CJ and Griffiths DJ : A decade of functional brain imaging applied to bladder control. Neurourol Urodyn 29 : 49─55, 2010
6) Takahashi O, Sakakibara R, Panicker J, et al : White matter lesions or Alzheimer’s disease : which contributes more to overactive bladder and incontinence in elderly adults with dementia? J Am Geriatr Soc 60 : 2370─2371, 2012
7) Sakakibara R, Kanda T, Sekido T, et al : Mechanism of bladder dysfunction in idiopathic normal pressure hydrocephalus. Neurourol Urodyn 27 : 507─510, 2008
8) Herzog J, Weiss PH, Assmus A, et al : Subthalamic stimulation modulates cortical control of urinary bladder in Parkinson’s disease. Brain 129 : 3366─3375, 2006
9) Sakakibara R, Tateno F, Kishi M, et al : Pathophysiology of bladder dysfunction in Parkinson’s disease. Neurobiol Dis, 2011[Epub ahead of print]
10) Madhuvrata P, Singh M, Hasafa Z, et al : Anticholinergic drugs for adult neurogenic detrusor overactivity : a systematic review and meta-analysis. Eur Urol, 2012[Epub ahead of print]
11) Marinkovic SP, Rovner ES, Moldwin RM, et al : The management of overactive bladder syndrome. BMJ 344 : e2365, 2012
12) Sakakibara R, Uchiyama T, Yamanishi T, et al : Dementia and lower urinary dysfunction : with a reference to anticholinergic use in elderly population. Int J Urol 15 : 778─788, 2008
13) Chancellor M and Boone T : Anticholinergics for overactive bladder therapy : central nervous system effects. CNS Neuroscience & Therapeutics 18 : 167─174, 2012
14) Sakakibara R, Ogata T, Uchiyama T, et al : How to manage overactive bladder in elderly individuals with dementia? A combined use of donepezil, a central AChE inhibitor, and propiverine, a peripheral muscarine receptor antagonist. J Am Geri Soc 57 : 1515─1517, 2009
15) Goulooze SC, Cohen AF and Rissmann R : Mirabegron. Br J Clin Pharmacol, 2015[Epub ahead of print]